The right tools at the right time.
暂无分享,去创建一个
[1] P. Howarth,et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. , 1992, The American review of respiratory disease.
[2] M. Kavuru,et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. , 2000, The Journal of allergy and clinical immunology.
[3] Andrew H. Liu. Consider the child: how early should we treat? , 2004, The Journal of allergy and clinical immunology.
[4] T. Koepsell,et al. Association of lower continuity of care with greater risk of emergency department use and hospitalization in children. , 2001, Pediatrics.
[5] F. Ducharme. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. , 2004, The Cochrane database of systematic reviews.
[6] M. Laviolette,et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. , 1999, American journal of respiratory and critical care medicine.
[7] Brigit VanGraafeiland,et al. National Asthma Education and Prevention Program. , 2002, The Nurse practitioner.
[8] B. Lipworth. Antagonism of long‐acting β2‐adrenoceptor agonism , 2002 .
[9] P. Jones,et al. Inhaled versus oral steroids for adults with chronic asthma , 2001 .
[10] S. Braman. Asthma in the elderly. , 2003, Experimental lung research.
[11] E. Salpeter,et al. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. , 2004, Chest.
[12] D. Fabian,et al. The global burden of asthma: executive summary of the GINA Dissemination Committee Report , 2004, Allergy.
[13] W. Busse,et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.
[14] P. Barnes,et al. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids , 2002, European Respiratory Journal.
[15] M. Weatherall,et al. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis , 2004, European Respiratory Journal.
[16] P. Kuna,et al. Long-Term Deterioration of Lung Function in Asthmatic Outpatients , 2004, Respiration.
[17] S. Pedersen,et al. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. , 1994, Respiratory medicine.
[18] J. Virchow,et al. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. , 2000, American journal of respiratory and critical care medicine.
[19] N Franklin Adkinson,et al. Long-term effects of budesonide or nedocromil in children with asthma. , 2000, The New England journal of medicine.
[20] T. Haahtela,et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. , 1994, The New England journal of medicine.
[21] R. Irwin,et al. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. , 1990, The American review of respiratory disease.
[22] Third Expert Panel on theDiagnosis,et al. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma , 1997 .
[23] S. Walker,et al. Anti-IgE for chronic asthma in adults and children. , 2006, The Cochrane database of systematic reviews.
[24] A. Woolcock,et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. , 1996, American journal of respiratory and critical care medicine.
[25] S. Suissa,et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. , 2000, The New England journal of medicine.
[26] E. Israel,et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients , 1999, BMJ.
[27] W. Calhoun,et al. Current outpatient management of asthma shows poor compliance with International Consensus Guidelines. , 1999, Chest.
[28] N. Barnes,et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. , 2004, American journal of respiratory and critical care medicine.
[29] K. Rabe,et al. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. , 2000, The European respiratory journal.
[30] W. Busse,et al. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. , 1999, The Journal of allergy and clinical immunology.
[31] R. Townley,et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. , 2001, The European respiratory journal.
[32] J. Bousquet,et al. Anti‐immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti‐inflammatory activity and clinical efficacy , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[33] R. Puy,et al. Allergen immunotherapy for asthma. , 2003, The Cochrane database of systematic reviews.
[34] R. Pauwels,et al. GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .
[35] E. Hey,et al. Underdiagnosis and undertreatment of asthma in childhood. , 1983, British medical journal.
[36] W. Lumry,et al. Combined Salmeterol 50 μ g and Fluticasone Propionate 250 μ g in the Diskus Device for the Treatment of Asthma , 2000 .
[37] C. Weel. Underdiagnosis of asthma and COPD: is the general practitioner to blame? , 2002 .
[38] J. Lanke,et al. Accuracy of a first diagnosis of asthma in primary health care. , 2002, Family practice.
[39] R. Pauwels,et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. , 2004, American journal of respiratory and critical care medicine.
[40] W. Busse,et al. Efficacy and safety of inhaled corticosteroids. New developments. , 1998, American journal of respiratory and critical care medicine.
[41] D. Strachan,et al. Prevalence of asthma symptoms, diagnosis, and treatment in 12–14 year old children across Great Britain (international study of asthma and allergies in childhood, ISAAC UK) , 1998, BMJ.
[42] P. O'Byrne,et al. A comparison of the efficacy and safety of inhaled corticosteroids in asthma , 1997, Allergy.
[43] M. Sears,et al. Potential masking effects of salmeterol on airway inflammation in asthma. , 1998, American journal of respiratory and critical care medicine.
[44] G. D. Cioppa,et al. Erratum: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics (European Respiratory Journal (2001) vol. 18 (254-261)) , 2001 .
[45] J. Kemp. Recent Advances in the Management of Asthma Using Leukotriene Modifiers , 2003, American journal of respiratory medicine : drugs, devices, and other interventions.
[46] R. Zeiger,et al. Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP) , 1999, The Journal of allergy and clinical immunology.
[47] F. V. D. Heijden,et al. Underdiagnosis of asthma: is the doctor or the patient to blame? The DIMCA project , 2000, Thorax.
[48] P. Barnes. Asthma guidelines: recommendations versus reality. , 2004, Respiratory medicine.
[49] T. Haahtela,et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. , 1991, The New England journal of medicine.